ICMR and Panacea Biotec begin Phase 3 clinical trial of India’s 1st indigenous dengue vaccine DengiAll | Mint – Mint

ICMR and Panacea Biotec begin Phase 3 clinical trial of India’s 1st indigenous dengue vaccine DengiAll | Mint  MintPanacea Biotec shares up 5% as phase-3 trial of India’s first dengue vaccine ‘DengiAll’ begins  UpstoxFirst-ever Phase 3 clinical trial of made-in-India dengue vaccine begins in India  The Financial ExpressNo Dengue vaccine in near future  Bangalore MirrorIndia’s first-ever dengue vaccine DengiAll enters Phase 3 clinical trial  Mathrubhumi English ICMR and Panacea Biotec begin Phase 3 clinical trial of India’s 1st indigenous dengue vaccine DengiAll | Mint  MintPanacea Biotec shares up 5% as phase-3 trial of India’s first dengue vaccine ‘DengiAll’ begins  UpstoxFirst-ever Phase 3 clinical trial of made-in-India dengue vaccine begins in India  The Financial ExpressNo Dengue vaccine in near future  Bangalore MirrorIndia’s first-ever dengue vaccine DengiAll enters Phase 3 clinical trial  Mathrubhumi English  Top stories – Google News